Related Experiment Video
Updated: Mar 24, 2026

Micro-scale Engineering for Cell Biology
Published on: October 1, 2007
Investor Outlook: After the Biotech Bubble Popped
Joshua Schimmer1, Steven Breazzano1, Jerry Yang1
1Piper Jaffray & Co. , New York, New York.
Abstract:
After a few torrid years of value appreciation, the biotech "bubble" has precipitously popped over the past few months. In this report, we take a look at some of the factors that drove the run-up in valuations, the triggers that led to their substantial pullback, and where the industry may be headed from here. Gene therapy/editing companies have been particularly affected by these dynamics, raising a new set of questions and challenges for the group.
More Related Videos
Related Concept Videos
Equity Theory
Drug Products: Biologics, Biosimilars and Interchangeables
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Production of Pharmaceuticals
Microorganisms in Medicine and Therapeutics
Biopharmaceutics and Pharmacokinetics: Overview

